Chemotherapy at first diagnosis of advanced prostate cancer – revolution or evolution? Findings from a British uro-oncology group UK survey to evaluate oncologists' views on first-line docetaxel in combination with androgen deprivation therapy in castrate-sensitive metastatic and high-risk/locally advanced prostate cancer by Davda, R. et al.
 
 
 
 
Davda, R., Hughes, S., Jones, R., Crabb, S.J., Troup, J., and Payne, H. 
(2016) Chemotherapy at first diagnosis of advanced prostate cancer – 
revolution or evolution? Findings from a British uro-oncology group UK 
survey to evaluate oncologists' views on first-line docetaxel in combination 
with androgen deprivation therapy in castrate-sensitive metastatic and high-
risk/locally advanced prostate cancer. Clinical Oncology, 28(6), pp. 376-
385. (doi:10.1016/j.clon.2016.01.006) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
 
 
 
http://eprints.gla.ac.uk/120016/ 
     
 
 
 
 
 
 
Deposited on: 22 June 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution 
or Evolution? Findings from a British Uro-oncology Group UK Survey to 
evaluate oncologists' views on first line docetaxel in combination with 
androgen deprivation therapy in castrate sensitive metastatic and high risk / 
locally advanced prostate cancer  
  
Reena Davda1, Simon Hughes2 Robert Jones3, Simon J. Crabb4, Janis Troup5,  
Heather Payne1 
 
 1Department of Oncology University College Hospital London, London, 2 Department of Oncology, 
Guy's and St. Thomas’ Hospitals, London, 3Institute of Cancer Sciences, University of Glasgow, 
Beatson West of Scotland Cancer Centre, Glasgow, 4Cancer Sciences Unit, University of Southampton, 
Southampton,5British Uro-oncology Group, London,  
 
 
INTRODUCTION 
 
The year 2004 was a turning point for the management of advanced or metastatic prostate cancer 
with the reporting of two positive phase III trials of docetaxel (1, 2).  Until then, treatment had been 
limited to androgen deprivation therapy (ADT) with the aims of symptom palliation and delaying 
disease progression. Cytotoxic chemotherapy with mitoxantrone and prednisolone (2) had 
demonstrated modest analgesic benefits, but no impact on overall survival (OS).  TAX 327 (1), 
alongside the SWOG 99-16 trial (2), marked the genesis of a new era for the uro-oncology 
community, providing hope on the horizon for patients with advanced prostate cancer.  The TAX 327 
trial demonstrated that docetaxel, with concomitant prednisolone, improved median overall survival 
in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) compared to mitoxantrone 
plus prednisolone (19.2 months v 16.3 months respectively; HR=0.79; p=0.0004) (3).  Now, a decade 
on, we see a proliferation of management options for mCRPC and the sequencing of these 
treatments is the subject of ongoing debate amongst oncologists and urologists (4-9).   
There is now increasing focus on earlier disease at the point where metastatic prostate cancer is not 
yet resistant to castration therapy. These patients are often fitter than those with CRPC, and may be 
better able to tolerate systemic therapy. Further, if the hazard ratios for OS can be translated from 
the CRPC to the castrate sensitive prostate cancer (CSPC) setting, then by virtue of being earlier in 
the patient’s lifespan they may make a greater contribution to improving OS. The addition of 
docetaxel to first-line ADT for men with metastatic CSPC has been the key question of three recently 
reported trials: GETUG-AFU-15 (10); E3805 CHAARTED (11) and STAMPEDE (12).   
The GETUG-AFU-15 study (10) randomised 385 men in a 1:1 ratio to receive continuous ADT alone or 
in combination with docetaxel (75 mg/m2) every 3 weeks for up to 9 cycles. After a median follow-
up of 50 months, there was no difference in OS: median 58.9 months in the ADT plus docetaxel 
group and 54.2 months for ADT alone group (HR = 1.01, 0.75-1.36).  A significant benefit was 
detected for docetaxel in the following secondary endpoints: median biochemical progression free 
survival (22.9 v 12.9 months; HR= 0.72 (0.57–0.91); p=0.005); clinical progression free survival (23.5 v 
15.4 months; HR= 0.75 (0.59–0.94); p=0.015).  However, with no benefit in the primary endpoint of 
OS, the group concluded that docetaxel should not be used as part of first-line treatment for 
patients with non-castrate-resistant metastatic prostate cancer.  The GETUG study also reported a 
21% incidence of febrile neutropenia. There were 4 treatment related deaths in the chemotherapy 
group, two of which were neutropenia related. Following this, the data monitoring committee 
recommended the use of granulocyte colony-stimulating factor after which there were no further 
treatment-related deaths. 
The E3805 CHAARTED trial (11) randomised 790 men equally to ADT alone verses ADT + docetaxel 
(75mg/m2 every 3 weeks for 6 cycles; no prednisolone).  Men started docetaxel within 4 months of 
the initiation of ADT and were stratified into high volume (HV) vs. low volume (LV) disease 
subgroups.  High volume disease was defined as visceral metastases and/or 4 or more bone 
metastases with at least one beyond the pelvis and vertebral column.   72.8% of men in both arms 
had received no prior local treatment for prostate cancer. Of those who had relapsed with 
metastatic disease following initial radical management, 4.5% of patients in the combined arm and 
4.1 % of patients in the ADT alone arm had been exposed to adjuvant hormone therapy. The study 
demonstrated a significant OS advantage for the docetaxel and ADT combination: median OS of 57.6 
months v 44.0 months (HR=0.61 (0.47-0.80); p<0.001).  The results from subgroup analyses showed 
an even greater benefit for men with HV disease with a 17 month improvement in median OS (49.2 
months v 32.2 months; HR=0.60 (0.45-0.81); p<0.001).  There was no significant difference in OS for 
the LV group (HR=0.60 (0.32-1.13); p=0.11) and the authors concluded that longer follow up will be 
required to determine whether a clinically significant benefit exists.  Use of granulocyte colony-
stimulating factor in CHAARTED was at the investigator’s discretion and the incidence of neutropenic 
fever in was 6% with one treatment related death. 
The GETUG group recently presented a retrospective re-analysis of their study according to the 
disease volume definitions used in CHAARTED, and with a longer median follow up of 82.9 months. 
The patient distribution between HV and LV differed to CHAARTED with HV patients accounting for 
47.5% of men in the GETUG study compared to 65% of men in CHAARTED. In GETUG, the number of 
men in the ADT-alone arm who subsequently received docetaxel on progression was higher at 80% 
compared to 34% in CHAARTED. Again there was no significant difference observed in OS, even on 
sub-group analysis based on disease volume. However, a non-significant 4 month increase in OS was 
seen in the underpowered HV group (39 months verses 35.1 months: HR=0.8 (0.6-1.2) p-0.35). 
Combining ADT and docetaxel again showed a significant benefit in terms of bPFS and cPFS (13).  
STAMPEDE is a novel study with a multi-arm, multi-stage (MAMS) design which has investigated a 
number of treatment strategies including the addition of docetaxel to ADT and compared this to 
standard of care (ADT alone). STAMPEDE included men with metastatic or node positive prostate 
cancer in addition to those with high risk locally advanced disease (defined as 2 or more of the 
following risk factors: T3/T4 or PSA≥40ng/ml or Gleason Score 8 -10) (12).  Men who had relapsed 
after previous radiotherapy or prostatectomy were eligible if they had one or more of the following 
progression factors: PSA≥ 4ng/ml and a PSA doubling time of less than 6 months, PSA ≥20ng/ml, 
positive nodal disease or metastases.  This study did not sub categorise high volume and low volume 
metastases. The assessment of ADT +/- docetaxel (75mg/m2 every 3 weeks for 6 cycles; 
prednisolone 10mg daily) took place between 2005 and 2013; with 1184 men randomised to ADT 
alone, and 592 to ADT and docetaxel.   
Results presented at the ASCO meeting 2015 showed that at a median follow up of 42 months there  
was a significant improvement in OS for the group receiving docetaxel and ADT in combination: 
median OS of 77 months v 67.0 months (HR=0.76 (0.63-0.91) p=0.003). This difference was even 
greater for men with metastatic disease with a reported 22 month increase in median OS from 43 
months to 65 months (HR= 0.73 (0.59-0.89) p=0.02).  For men with non-metastatic disease, there 
were only 93 OS events at the data cut so it was too early to determine significance.  There were 
also significant benefits seen in terms of Failure Free Survival (FFS), defined as the first of the 
following events: PSA failure, local failure, lymph node failure, distant metastases or prostate cancer 
death.  The results for the entire group reported a median FFS of 21 months for the ADT arm and 37 
months for the ADT and docetaxel group (HR=0.62 (0.54-0.70) p=<0.0000000001).  For the non-
metastatic group, the FFS benefit had a significant HR of 0.57 (0.42 – 0.76). The toxicity was higher 
for the docetaxel combination with 51% Grade 3+ events compared to 31% for ADT alone and a 12% 
rate of febrile neutropenia. The STAMPEDE results demonstrated that docetaxel improved OS for 
CSPC and the conclusion was that this should be considered standard of care for suitable men with 
newly diagnosed metastatic prostate cancer. Publication of this STAMPEDE data in a peer reviewed 
journal is awaited.  
Up front chemotherapy combined with ADT may effectively treat hormone-resistant cells at 
diagnosis, potentially achieving a prolonged initial response. First line combination chemotherapy 
with ADT would result in more men receiving chemotherapy earlier in their disease course, when 
potentially fitter and better able to tolerate treatment. However, some men at low risk of death 
from prostate cancer may never require chemotherapy and may be unnecessarily exposed to the 
toxicity of this treatment.  
This original paper presents data from a survey of members of the British Uro-oncology Group (BUG) 
which assessed whether uro-oncologists’ practice has changed or may be likely to change in the 
future in various clinical settings based on the findings reported from GETUG-AFU-15, E3805 
CHAARTED and STAMPEDE. 
 
MATERIALS AND METHODS 
BUG issued a semi-structured online questionnaire, comprising 21 questions, to its membership of 
specialist urological oncologists (see Appendix 1). The survey was written by the authors to reflect 
the data from the recent studies. The majority of questions were multiple-choice, allowing the 
respondent one answer.  For questions asking oncologists for factors influencing their decisions, a 
free text box was provided. The questionnaire was sent via e-mail link to 160 uro-oncologists 
practising across the UK. The initial invitation to participate was send two weeks following oral 
presentation of the STAMPEDE data at the ASCO annual meeting, June 2015. Links to the abstracts 
of GETUG-AFU-15, E3805 CHAARTED and STAMPEDE were attached with the survey for respondents 
to review prior to completing the survey. The questionnaire link remained open until 30 September 
2015, following which the responses were analysed.  
 
RESULTS    
Participants 
One hundred and eleven participants completed the survey, all confirming that they treat prostate 
cancer.  Across the country, there was a wide range in the volume of new cases of metastatic 
prostate cancer discussed annually in local MDT meetings, as shown in figure 1a.  In these MDTs, 
most individual oncologists see between 50 and 100 new patients each year (figure 1b). 
 
Patient population  
 
Of the new cases of metastatic prostate cancer discussed at local MDT each year, most oncologists 
believe that that over 25% have high volume disease (by the CHAARTED criteria) (figure 1c).  Eighty-
nine per cent of oncologists felt between 26-76% of their patients would be considered medically fit 
to receive docetaxel chemotherapy (regardless of whether or not they may be willing to receive 
chemotherapy) (figure 1d). 
 
Influence of CHAARTED / STAMPEDE on clinical practice 
 
A third of the participants said that the CHAARTED study had influenced their clinical practice during 
the past 12 months (Figure 2a) while 87% stated that STAMPEDE will influence their clinical practice 
in the future (Figure 2b).  
  
When asked how many patients with metastatic prostate cancer the clinicians had treated with 
docetaxel in combination with ADT as first line therapy in the past 12 months, 47% of oncologists 
answered none, whereas 47% had treated 1-10 patients, and 5% had treated more than 10 patients 
(Figure 2c). 
Participants were asked to consider whether, if funded, they would offer docetaxel in combination 
with ADT as first line therapy for hormone sensitive disease in the future. Four different clinical 
scenarios were given, based on the data reported from the CHAARTED and STAMPEDE studies.  
When asked if they would offer the combination treatment to men with high volume metastatic 
prostate cancer 96% of the participants replied “Yes”, with 4% answering “possibly” (figure 3a). 
Additionally 54% of respondents stated that they anticipated delivering this treatment to over 50% 
of men presenting with HV metastatic disease (figure 3b). 
However, only 46% of clinicians stated that they would offer the docetaxel/ADT combination as a 
first line therapy to men with low volume metastatic prostate cancer, another 46% stating that they 
would “possibly” offer this regimen (figure 3c). The proportion of men with LV metastatic disease 
that respondents anticipated treating with the combination was also lower with only 22% 
anticipating treating over 50% of men (figure 3d). 
The third scenario concerned men with non-metastatic locally advanced prostate cancer (defined as 
node positive or at least 2 of: T3/4; PSA ≥ 40; Gleason ≥ 8.  Only 14% of oncologists replied that they 
would offer the docetaxel combination treatment as first-line therapy, although 54% stated it was a 
possibility, 12% did not know and 19% of respondents would not offer this treatment (figure 3e). 
Of those respondents who would treat men with non-metastatic disease, the proportions of such 
men they anticipated delivering docetaxel chemotherapy to are shown in figure 3f. 
Finally, regarding treatment with docetaxel in combination with ADT as first line therapy for men 
with metastatic progression who have previously received radical treatment (Prostatectomy or 
Radiotherapy). Forty-six percent of the respondents would use this regimen, and 39% would 
“possibly” use it (figure 3g). When asked what proportion of these men they anticipate treating with 
the first line combination 33% stated up to 25% of patients, 31% stated between 25 and 50% of 
patients, and 15% stated between 50 and 75% of patients (Figure 3h). 
The Oncologists were also asked to estimate how many additional patients they will treat with first 
line ADT and docetaxel over the next 12 months, 51% of clinicians expect to treat up to 25 additional 
patients, 20% expect to treat 26-50 patients, and 19% predict the number of patients to be over 50 
(Figure 4).  
 Factors influencing clinical decisions 
The survey included 4 questions regarding key factors that influenced the uro-oncologists’ decisions 
to treat with up front docetaxel in the 4 differing clinical settings. 
In the de-novo metastatic settings, reported factors included patient fitness, performance status, 
comorbidities, age, life expectancy, disease volume / burden (especially visceral metastases), 
Gleason score, PSA level, the presence of up to date to guidelines, and patient preference.  
In both the non-metastatic setting and in the metastatic progression post radical treatment setting, 
factors included funding, patient fitness, performance status, comorbidities, age, bulk of nodal 
disease, histological risk factors / Gleason score, PSA level, STAMPEDE overall survival data and 
patient preference.  
 
DISCUSSION  
This survey reports oncologists’ attitudes towards a major change in practice in the standard of care 
for men with newly diagnosed advanced prostate cancer in the UK. Following the oral and abstract 
presentations of the STAMPEDE chemotherapy data, 96% of oncologists indicated that they would 
offer docetaxel in combination with ADT as a first line therapy option to suitable men with high 
volume metastatic prostate cancer.  A significant proportion of these patients are considered fit for 
this treatment. However, only 46% of respondents would also offer this therapy to men with low 
volume metastatic disease. This response would seem likely to reflect the sub-group analysis of OS in 
low volume disease in the CHAARTED study which did not show a statistically significant difference. 
However, as a counter argument, the hazard ratio in this subgroup is similar in CHAARTED to the HV 
subgroup. Furthermore, the data are likely to be immature simply because LV patients were added 
into the CHAARTED trial as a protocol amendment during its recruitment and will inevitably 
experience events at a later point. STAMPEDE, which showed a survival advantage in its M1 
subgroup as a whole has not presented data on a HV/LV split (and was not set up to do so). However 
this distinction seems to remain as a decision making factor in many oncologists minds. 
There is more uncertainty as to whether combined docetaxel and ADT as first line therapy for men 
with non-metastatic disease will be adopted into practice in the UK despite an advantage in FFS. This 
caution may stem from the absence of an overall survival benefit for chemotherapy in men with 
non-metastatic but locally advanced or high risk localised disease. The use of chemotherapy in the 
adjuvant setting following radiotherapy has been investigated in RTOG 0521 which randomised men 
with high risk prostate cancer to ADT plus radical radiotherapy or ADT plus radical radiotherapy plus 
6 cycles of adjuvant docetaxel at 75 mg/m2 with prednisolone commencing 4 weeks following the 
completion of radiotherapy. Results were reported at ASCO General Meeting 2015 (13). Four year 
OS rates were 89% [95% CI: 84-92%] in the ADT plus radiotherapy arm and 93% [95% CI: 90-96%] in 
the ADT plus radiotherapy plus docetaxel arm (1-sided p = 0.03, HR = 0.68 0.44-1.03). Prostate 
cancer specific mortality was better than expected in the design of the study and longer follow-up is 
required to clearly understand the benefit docetaxel adds in this population. 
Various factors influenced uro-oncologists’ decision to offer first line chemotherapy in combination 
with ADT. Key themes were patient related factors including co-morbidities, performance status and 
patient preference, and disease related factors such as Gleason grade, PSA and bulk of metastatic 
disease. As well as evidence presented from GETUG-15; CHAARTED and STAMPEDE, British uro-
oncologists also need to consider UK funding issues when offering new management strategies. This 
is not just for docetaxel itself, but they also need to address the increase workload associated with 
additional men receiving early chemotherapy which will have implications on the workload of 
oncologists and that of chemotherapy units. 
Nationally, discussions are taking place on how units can best expand services with resource 
limitations to implement this change in clinical practice. In the survey, respondents proposed a need 
for updated national guidelines which may facilitate this.  
Findings from the survey indicate the results from the three studies (GETUG-15; CHAARTED and 
STAMPEDE) will have an impact on the future management of patients with metastatic prostate 
cancer. The survey highlighted the complexities surrounding the clinical implementation of the data 
from these studies, including changes in referral pathways with the early involvement of oncologists 
in such patients’ care, increases in workloads for oncologists and chemotherapy units and the need 
for national approval for re-imbursement of these treatments. The uro-oncology community is 
engaged with emerging evidence to attain access for early chemotherapy for all suitable patients 
across the UK.  Oncologists and urologists, together with the whole MDT, need to work within the 
boundaries of reimbursement and access regulations, individualising treatment for patients’ needs.   
 
CONCLUSION 
We have witnessed a ‘revolution’ with powerful new data redefining standard of care.  The evolution 
in the management of advanced prostate cancer continues. Without doubt, 2014-2015 represents 
another significant turning point in improving the management of patients with advanced prostate 
cancer.  BUG aims to continue to share best practice and thanks its membership for contributing to 
this project.  
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Appendix 1: online survey questions 
BUG Survey: Chemotherapy and Androgen Deprivation Therapy (ADT) for Advanced 
Prostate Cancer  
There have been recent developments in the management of metastatic (advanced) prostate 
cancer. The abstracts from three studies investigating the use of initial chemotherapy are detailed 
below if you wish to copy and paste to open in your web browser. Two of these trials have now 
demonstrated a survival advantage when docetaxel is given in combination with androgen 
deprivation therapy (ADT) for first line therapy. 
 
On behalf of the British Uro-oncology Group (BUG), we would be grateful if you would answer the 
questions in this survey. Your answers will be anonymous, but the pooled results will hopefully help 
us to try and determine whether these three studies have already influenced, or are likely to 
influence, future uro-oncology practice in the UK. 
 
* Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer 
(GETUG-AFU 15): a randomised, open-label, phase 3 trial. 
http://www.ncbi.nlm.nih.gov/m/pubmed/23306100/ 
 
* CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive 
Disease in Prostate Cancer  
http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/LBA2?sid=c963c9ed-cf5b-4a5f-
b1bd-f6adf75e0f80 
 
* Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results 
from STAMPEDE 
http://abstracts.asco.org/156/AbstView_156_147721.html 
 
1. Do you treat prostate cancer? 
• Yes 
• No 
 
2. Approximately how many new cases of metastatic prostate cancer are discussed at your MDT in a 
year? 
• 1-50 
• 51-100 
• 101-200 
• 200-300 
• >300 
 
3. Approximately what proportion of the cases referred to in Question 2 have HIGH volume disease 
(defined as visceral metastases and/or more than 4 bone metastases at least one of which is outside 
the pelvis or spine)? 
• <15% 
• 15 – 25% 
• 26 – 35% 
• 36 – 50% 
• 51 – 75% 
• >75% 
 
4. Approximately what proportion of the cases referred to in Question 2 would you consider 
medically fit to receive docetaxel (regardless of whether or not they may be willing)? 
• <25% 
• 26 – 50% 
• 51 – 75% 
• >75% 
 
5. Approximately how many men with metastatic prostate cancer are referred to your personal 
practice in a year? 
• 1-25 
• 51-100 
• 101-200 
• >200 
 
6. Has the CHAARTED data influenced your clinical practice in the last 12 months? 
• Yes 
• No 
• Possibly 
• Don’t Know 
 
7.  Within your personal practice, how many patients with metastatic prostate cancer have you 
treated with docetaxel in combination with ADT as first line therapy in the past 12 months? 
• None 
• 1-10 
• 11-20 
• 21-50 
• >50 
List any factors that have influenced your answer to Question 7:……………………………………………………… 
 
8. Will the STAMPEDE docetaxel data influence your clinical practice in the future? 
• Yes 
• No 
• Possibly 
• Don’t know 
 
9. If funded, would you offer docetaxel in combination with ADT as a first line therapy option to men 
with HIGH volume metastatic prostate cancer in the future? (defined as visceral metastases and/or 4 
or more bone metastases with at least 1 beyond pelvis and vertebral column) 
• Yes 
• No 
• Possibly 
• Don’t know 
 
10. In your personal practice, what proportion of men with HIGH volume metastatic prostate cancer 
do you anticipate that you will treat with first line combination ADT and docetaxel in the future? 
• None 
• 1-25% 
• 26-50% 
• 51-75% 
• 76-100% 
• Don’t know 
 
11. In this setting: 
Please list any factors that could influence your decision to treat with first line chemotherapy in 
combination with ADT 
 
Please list any factors that could influence your decision NOT to treat with first line chemotherapy in 
combination with ADT 
 
12. If funded, would you offer docetaxel in combination with ADT as a first line therapy option to 
men with LOW volume metastatic prostate cancer in the future? 
• Yes 
• No 
• Possibly 
• Don’t know 
 
13. In your personal practice, what proportion of men with LOW volume metastatic prostate cancer 
do you anticipate that you will treat with first line combination ADT and docetaxel in the future? 
None 
• 1-25% 
• 26-50% 
• 51-75% 
• 76-100% 
• Don’t know 
 
14. In this setting: 
Please list any factors that could influence your decision to treat with first line chemotherapy in 
combination with ADT 
 
Please list any factors that could influence your decision NOT to treat with first line chemotherapy in 
combination with ADT 
 
15. If funded would you offer docetaxel in combination with ADT as first line therapy for men with 
nonmetastatic locally advanced prostate cancer in the future (defined as node positive or at least 2 
of: T3/4 or PSA ≥ 40 or Gleason ≥ 8)? 
• Yes 
• No 
• Possibly 
• Don’t know 
 
16. In your personal practice, what proportion of men with non-metastatic locally advanced prostate 
cancer do you anticipate that you will treat with first line combination ADT and docetaxel in the 
future? 
• None 
• 1-10% 
• 11-25% 
• 26-50% 
• 51-75% 
• 76-100% 
• Don’t Know 
 
17. In this setting: 
Please list any factors that could influence your decision to treat with first line chemotherapy in 
combination with ADT 
 
Please list any factors that could influence your decision NOT to treat with first line chemotherapy in 
combination with ADT 
 
18. If funded, would you offer docetaxel in combination with ADT as first line therapy for metastatic 
progression to men who have previously been treated with radical prostatectomy (RP) or radical 
radiotherapy (RT)? 
• Yes 
• No 
• Possibly 
• Don’t know 
 
19. In your personal practice, what proportion of men who progress to develop metastatic prostate 
cancer, after primary therapy with RP or RT, do you anticipate that you will treat with first line 
combination ADT and docetaxel in the future? 
• None 
• 1-25% 
• 26-50% 
• 51-75% 
• 76-100% 
• Don’t Know 
 
20. In this setting: 
Please list any factors that could influence your decision to treat with first line chemotherapy in 
combination with ADT for metastatic progression 
 
Please list any factors that could influence your decision NOT to treat with first line chemotherapy in 
combination with ADT for metastatic progression 
 
21. How many additional patients do you anticipate that you will treat with first line ADT and 
docetaxel in the next 12 months? 
• None 
• 1-10 
• 11-25 
• 26-50 
• >50 
• Don’t know 
 
